{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood&page=15",
    "query": {
      "intervention": "Blood",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 20635,
    "total_pages": 2064,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T04:08:50.519Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04583072",
      "title": "Stockholm3 Validation Study in a Multi-Ethnic Cohort",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer (Diagnosis)"
      ],
      "interventions": [
        {
          "name": "The Stockholm3 test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Karolinska Institutet",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "45 Years to 75 Years · Male only"
      },
      "enrollment_count": 2152,
      "start_date": "2019-12-15",
      "completion_date": "2023-07-15",
      "has_results": false,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-10-21T04:08:50.519Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04583072"
    },
    {
      "nct_id": "NCT00141739",
      "title": "Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft-Versus-Host Disease"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "1 Year to 60 Years"
      },
      "enrollment_count": 100,
      "start_date": "2004-08",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-10-21T04:08:50.519Z",
      "location_count": 2,
      "location_summary": "Maywood, Illinois • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141739"
    },
    {
      "nct_id": "NCT00176839",
      "title": "Stem Cell Transplantation for Hematological Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Leukemia, Lymphocytic, Acute",
        "AML",
        "MDS"
      ],
      "interventions": [
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "ATG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "Up to 35 Years"
      },
      "enrollment_count": 11,
      "start_date": "2000-06-07",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-10-21T04:08:50.519Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176839"
    },
    {
      "nct_id": "NCT00980239",
      "title": "HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liver Cancer",
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 115,
      "start_date": "2009-09",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2015-11-11",
      "last_synced_at": "2026-10-21T04:08:50.519Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00980239"
    },
    {
      "nct_id": "NCT00025181",
      "title": "Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Intraocular Melanoma",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "MART-1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tyrosinase peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 19,
      "start_date": "2001-10",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2014-05-22",
      "last_synced_at": "2026-10-21T04:08:50.519Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025181"
    },
    {
      "nct_id": "NCT00983619",
      "title": "A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-cell Malignancies",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "MEDI-551",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 136,
      "start_date": "2010-04-16",
      "completion_date": "2019-03-21",
      "has_results": true,
      "last_update_posted_date": "2020-05-13",
      "last_synced_at": "2026-10-21T04:08:50.519Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Washington D.C., District of Columbia + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00983619"
    },
    {
      "nct_id": "NCT02763761",
      "title": "An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Melanoma",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Infliximab + Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone + Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-08-16",
      "completion_date": "2017-03-31",
      "has_results": false,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-10-21T04:08:50.519Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02763761"
    },
    {
      "nct_id": "NCT00923741",
      "title": "Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Talactoferrin",
          "type": "DRUG"
        },
        {
          "name": "Apheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 10,
      "start_date": "2008-06-19",
      "completion_date": "2010-02-01",
      "has_results": false,
      "last_update_posted_date": "2018-07-05",
      "last_synced_at": "2026-10-21T04:08:50.519Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923741"
    },
    {
      "nct_id": "NCT03118466",
      "title": "Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AML"
      ],
      "interventions": [
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 41,
      "start_date": "2017-09-25",
      "completion_date": "2021-08-18",
      "has_results": true,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-10-21T04:08:50.519Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03118466"
    },
    {
      "nct_id": "NCT01371656",
      "title": "Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Leukemias of Ambiguous Lineage",
        "Bacterial Infection",
        "Diarrhea",
        "Fungal Infection",
        "Musculoskeletal Complications",
        "Neutropenia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies"
      ],
      "interventions": [
        {
          "name": "levofloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 624,
      "start_date": "2011-09",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2020-12-07",
      "last_synced_at": "2026-10-21T04:08:50.519Z",
      "location_count": 78,
      "location_summary": "Little Rock, Arkansas • Downey, California • Duarte, California + 65 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01371656"
    }
  ]
}